Surgery and adjunctive chemotherapy for invasive bladder cancer

Area of Science:

• Oncology
• Urologic Oncology
• Cancer Treatment

Background:

• Invasive bladder cancer frequently metastasizes early, leading to high mortality despite local treatments like radiotherapy or cystectomy.
• Approximately 50% of patients with localized invasive bladder cancer succumb to the disease.
• Systemic chemotherapy has been explored for 25 years to enhance cure rates when combined with local therapies.

Purpose of the Study:

• To review the efficacy of systemic chemotherapy in conjunction with definitive local treatment for invasive bladder cancer.
• To analyze published data on neoadjuvant and adjuvant chemotherapy trials.
• To develop a practical management paradigm for patients with invasive bladder cancer.

Main Methods:

• Review of published non-randomized phase I-II and randomized clinical trials.
• Analysis of data on tumor down-staging, survival benefit, and methodological flaws in adjuvant chemotherapy trials.
• Synthesis of findings to construct a patient management strategy.

Main Results:

• Non-randomized trials indicate promising tumor down-staging with combined chemotherapy.
• Many randomized trials have not demonstrated a statistically significant survival benefit from adjunctive chemotherapy.
• Recent trials show a survival benefit from neoadjuvant combination chemotherapy, though not dramatic; adjuvant trials remain inconclusive due to flaws.

Conclusions:

• Neoadjuvant chemotherapy offers a survival benefit for invasive bladder cancer, though improvements are modest.
• Adjuvant chemotherapy trials have been hampered by methodological issues, yielding inconclusive survival data.
• A practical management paradigm is proposed, integrating current evidence on systemic chemotherapy for invasive bladder cancer.